In a general aspect, methods and devices are provided for using mass spectrometry to identify endometriosis. In some aspects, a fixed or discrete volume of a solvent is applied to a tissue site including possible endometriosis tissue. The applied solvent is collected to obtain a liquid sample. The liquid sample is subjected to mass spectrometry analysis. The liquid sample is collected from a tissue site in vivo during a medical procedure. The mass spectrometry data are analyzed to identify whether the tissue site comprises endometriosis.

A hormone mass spectrometric detection method based on antibody-coupled enrichment technology. The method includes the following steps: coupling antibodies and magnetic beads, adding a high-concentration methanol solution, removing endogenous hormone small molecule compounds carried on the antibodies by vortex, then restoring the activity of the antibodies to obtain antibody magnetic beads that can enrich hormone small molecule compounds. The antibodies are immobilized by magnetic beads and cooperate with the 80% methanol aqueous solution to elute hormone small molecule compounds, and then the hormone small molecule compounds are tested by mass spectrometry, thereby improving the specificity of test.

The present disclosure relates to CO.sub.2-based chromatography for the efficient and precise separation of Vitamin D metabolites.

Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

The invention relates to the detection of vitamin D metabolites. In a particular aspect, the invention relates to methods for detecting derivatized vitamin D metabolites by mass spectrometry.

An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with evaporative light scattering detection (ELSD); the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.

A method of detecting particles (1), e.g. proteins, after separation of particles based on their specific features, e.g. charge, size, shape, density, as series of single light scattering events created by the individual particles is described. The particles (1) are separated from each other along the separation path (11) and particles have specific arrival times at the target side depending on the particle features. The detecting step comprises an interferometric sensing of the light scattered at individual particles bound or transient in the detection volume (30). Parameters of the scattering light signals e.g. the interferometric contrast are analysed for obtaining specific particle features, e.g. size, mass, shape, charge, or affinity of the particles (1). Furthermore, a detection apparatus (100) being configured for detecting particles (1) is described.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

A method for testing for the presence and quantification of A1-type beta-casein variants or A2-type beta-caseins, in milk and milk derived dairy products, using chymotrypsin digestion followed by LC-MS analysis to determining the concentrations of beta-casein digestion peptides and using the concentrations to calculate the amounts of A1-type beta-casein variants or A2-type beta-casein variants present.

The present invention discloses a method for predicting the postoperative risk of brain-injured patients and a use of steroids/proteins for predicting the postoperative risk of brain-injured patients, mainly for testing the concentration of steroids/protein in patient samples. Acquire one-day in-vitro waste cerebrospinal fluid samples from brain-injured patients after surgery and conduct specific steroid and protein concentration tests. By confirming the concentration of specific steroid in the waste cerebrospinal fluid samples or the type and concentration of proteins detected therein, the postoperative risks of brain-injured patients can be predicted.